Phase 1/2 study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors
CONCLUSIONS: Navitoclax in combination with trametinib was tolerable. Durable clinical responses were observed in patients with RAS-mutant GYN cancers, warranting further evaluation in this population.PMID:38456660 | DOI:10.1158/1078-0432.CCR-23-3135
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Ryan B Corcoran Khanh T Do Jeong E Kim James M Cleary Aparna R Parikh Oladapo O Yeku Niya Xiong Colin D Weekes Jennifer Veneris Leanne G Ahronian Gianluca Mauri Jun Tian Bryanna L Norden Alexa G Michel Emily E Van Seventer Giulia Siravegna Kyle Camphausen Source Type: research
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Lung Cancer | Non-Small Cell Lung Cancer | Pancreas | Pancreatic Cancer | Study | Thrombocytopenia